Bruton Tyrosine Kinase Inhibitors for Systemic Lupus Erythematosus: A Systematic Review of Randomized Controlled Trials.

What was studied

This review looked at drugs that block BTK in systemic lupus. It covered randomized trials. The team searched PubMed, Embase and Cochrane Library on January 20, 2026. 579 records were screened and 5 trials met the criteria. The drugs were elsubrutinib, evobrutinib, fenebrutinib and orelabrutinib.

What they found

Results varied across lupus endpoints. Elsubrutinib and orelabrutinib regimens improved skin disease. Evobrutinib and fenebrutinib showed limited or non-significant differences from placebo. Safety was generally acceptable. Side effects included infections and raised liver enzyme levels.

What it means for patients

The authors say BTK blockers showed varied effects in lupus. They say these drugs have a potential to improve skin disease. They say no trial has tested them in cutaneous lupus. They call for trials aimed at cutaneous lupus.

Why it is not certain yet

Only 5 trials were found. They tested different drugs. Effects were variable. The abstract does not give the size of the trials. A review can only be as good as the trials in it.

Source

Bruton Tyrosine Kinase Inhibitors for Systemic Lupus Erythematosus: A Systematic Review of Randomized Controlled Trials.

We restate facts from the source record in our own words. The original wording belongs to its publisher.